Literature DB >> 16294008

Distinct specificities of pRb phosphorylation by CDK4 activated by cyclin D1 or cyclin D3: differential involvement in the distinct mitogenic modes of thyroid epithelial cells.

Sabine Paternot1, Tatjana Arsenijevic, Katia Coulonval, Laurence Bockstaele, Jacques E Dumont, Pierre P Roger.   

Abstract

Two distinct mitogenic modes coexist in the physiologically relevant model of primary cultures of dog thyroid epithelial cells. The differentiation-associated mitogenic stimulation by TSH and cAMP specifically requires the assembly and activation of cyclin D3-cyclin-dependent kinase (CDK)4 associated to p27(kip1), while the dedifferentiating proliferation induced by growth factors is associated with induction of cyclin D1. Here, we suggest that the related CDK "inhibitors" p21(cip1) and p27 are differentially utilized as positive CDK4 regulators in these mitogenic stimulations. p21 was induced by EGF + serum, but repressed by TSH, which, as previously shown, upregulates p27. In response to EGF + serum, p21 supported the nuclear localization, phosphorylation and pRb-kinase activity of CDK4. Unexpectedly, partly different site-specificities of pRb-kinase activity, leading to similar differences in the phosphorylation pattern of pRb in intact cells, were associated with cyclin D3-CDK4 bound to p27 in TSH-stimulated cells, or with CDK4 bound to p21 in growth factor-stimulated cells. These differences were ascribed to the predominant association of the latter complex to cyclin D1. Indeed, in different cell types and species, cyclin D1 varied from cyclin D3 by more efficiently driving the phosphorylation of pRb at sites (Ser807/811 and Thr826) required for its electrophoretic mobility shift. Therefore, different D-type cyclins could differently impact some pRb functions, which should be considered not only in the understanding of the relationships between cell cycle and differentiation expression in the distinct mitogenic modes of thyroid cells, but also in various development or differentiation models associated with dramatic switches in the expression of individual D-type cyclins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16294008     DOI: 10.4161/cc.5.1.2265

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.

Authors:  Ana Sofia Rocha; Sabine Paternot; Katia Coulonval; Jacques E Dumont; Paula Soares; Pierre P Roger
Journal:  Mol Biol Cell       Date:  2008-09-17       Impact factor: 4.138

2.  Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.

Authors:  Celine J Guigon; Laura Fozzatti; Changxue Lu; Mark C Willingham; Sheue-Yann Cheng
Journal:  Carcinogenesis       Date:  2010-03-18       Impact factor: 4.944

3.  Regulated activating Thr172 phosphorylation of cyclin-dependent kinase 4(CDK4): its relationship with cyclins and CDK "inhibitors".

Authors:  Laurence Bockstaele; Hugues Kooken; Frederick Libert; Sabine Paternot; Jacques E Dumont; Yvan de Launoit; Pierre P Roger; Katia Coulonval
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

4.  The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.

Authors:  Sabine Paternot; Bianca Colleoni; Xavier Bisteau; Pierre P Roger
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B.

Authors:  Balachandar Venkatesan; Nandini Ghosh-Choudhury; Falguni Das; Lenin Mahimainathan; Amrita Kamat; Balakuntalam S Kasinath; Hanna E Abboud; Goutam Ghosh Choudhury
Journal:  FASEB J       Date:  2008-06-20       Impact factor: 5.191

6.  Differential roles of cyclin D1 and D3 in pancreatic ductal adenocarcinoma.

Authors:  Nikolina Radulovich; Nhu-An Pham; Dan Strumpf; Lisa Leung; Wing Xie; Igor Jurisica; Ming-Sound Tsao
Journal:  Mol Cancer       Date:  2010-02-01       Impact factor: 27.401

7.  Cell cycle actions of parathyroid hormone-related protein in non-small cell lung carcinoma.

Authors:  Randolph H Hastings; Philippe R Montgrain; Rick Quintana; Yvette Rascon; Leonard J Deftos; Erin Healy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-07-24       Impact factor: 5.464

8.  Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21(Cip1/WAF1) and p27 (Kip1).

Authors:  Min Wei; Bingya Liu; Qinlong Gu; Liping Su; Yingyan Yu; Zhenggang Zhu
Journal:  Cell Oncol (Dordr)       Date:  2012-11-27       Impact factor: 6.730

9.  Lineage specific composition of cyclin D-CDK4/CDK6-p27 complexes reveals distinct functions of CDK4, CDK6 and individual D-type cyclins in differentiating cells of embryonic origin.

Authors:  V Bryja; J Pacherník; J Vondráček; K Souček; L Čajánek; V Horvath; Z Holubcová; P Dvořák; A Hampl
Journal:  Cell Prolif       Date:  2008-12       Impact factor: 6.831

10.  CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.

Authors:  Xavier Bisteau; Sabine Paternot; Bianca Colleoni; Karin Ecker; Katia Coulonval; Philippe De Groote; Wim Declercq; Ludger Hengst; Pierre P Roger
Journal:  PLoS Genet       Date:  2013-05-30       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.